Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034281 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
A Phase 1 study of Breast Neoplasm and Pancreatic Neoplasm, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 4
- Study locations
NCT00034281: Completed Phase 1 study of Breast Neoplasm and Pancreatic Neoplasm, sponsored by Takeda.
NCT00034281 is a Phase 1 study of Breast Neoplasm and Pancreatic Neoplasm that has completed, run by Takeda. The registered enrollment target is 16 participants, below the 162-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00034281, a Phase 1 study of Breast Neoplasm and Pancreatic Neoplasm, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to investigate a safe dose of TAK-165, once daily (QD), in patients with HER2-tumor expression.
Conditions Studied
Interventions
- DRUG TAK-165
Study Locations (4)
Texas
- The Institute for Drug Development - San Antonio
- Brooke Army Medical Center/Drug Development Unit - San Antonio
- South Texas VA, Audie Murphy Division - San Antonio
Arizona
- Arizona Cancer Center - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2002-06 |
| Est. Completion | 2003-09 |
| Phase | Phase 1 |
What the finished NCT00034281 record still lists
NCT00034281 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 162-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (90% lower).
The record links to 5 conditions, with Breast Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which TAK-165 is the first listed.
NCT00034281 reports a single indexed study location in Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT00034281 about?
NCT00034281 is a clinical study titled "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2". The purpose of this study is to investigate a safe dose of TAK-165, once daily (QD), in patients with HER2-tumor expression.
What is the current status of trial NCT00034281?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2002-06. Estimated completion is 2003-09.
What conditions does trial NCT00034281 study?
This clinical trial studies the following conditions: Breast Neoplasm, Pancreatic Neoplasm, Lung Neoplasm, Ovarian Neoplasm, Renal Neoplasm.
What interventions are being tested in trial NCT00034281?
The interventions under investigation include: TAK-165 (DRUG).
Who is sponsoring clinical trial NCT00034281?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00034281 being conducted?
This trial has 4 study locations across Arizona, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00034281's enrollment target sits among peer trials
16 27th of 26 the lowest of 26 other Breast Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
RECRUITING · Phase 1
-
[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
-
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
[18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy
COMPLETED · Phase 1
-
Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia